Alnylam Pharmaceuticals
ALNY
391 hedge funds and large institutions have $15.4B invested in Alnylam Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 150 increasing their positions, 116 reducing their positions, and 37 closing their positions.
54% more call options, than puts
Call options by funds: $83.9M | Put options by funds: $54.4M
49% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 37
29% more repeat investments, than reductions
Existing positions increased: 150 | Existing positions reduced: 116
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
10% more capital invested
Capital invested by funds: $14B → $15.4B (+$1.4B)
4% more funds holding
Funds holding: 376 → 391 (+15)
0.55% more ownership
Funds ownership: 92.99% → 93.53% (+0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$219M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$142M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$64.4M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$52.7M |
| 5 |
Swedbank
Stockholm,
Sweden
|
+$51.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$137M |
| 2 |
1WCM
12 West Capital Management
New York
|
-$95.5M |
| 3 |
Dodge & Cox
San Francisco,
California
|
-$47.9M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$45.3M |
| 5 |
MC
Maverick Capital
Dallas,
Texas
|
-$28.3M |
ALNY Hedge Fund Activity: Q1 2021 in Review
391 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2021, worth a combined $15.4B — up 10% from $14B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALNY positions and 37 closed out — a net gain of 18 holders — while 150 added to existing stakes and 116 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $219M. The largest seller was Wellington Management Group, cutting an estimated $137M.
- 391 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2021, up from 376 in Q4 2020.
- Funds reported $15.4B of Alnylam Pharmaceuticals stock for Q1 2021, up 10% quarter-over-quarter.
- 55 funds opened new Alnylam Pharmaceuticals positions in Q1 2021 and 37 closed out, a net change of +18 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2021 was Fidelity Investments, an estimated $219M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2021 was Wellington Management Group, an estimated $137M sold.
Based on aggregated 13F filings for Q1 2021.